On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > BUSINESS
BUSINESS
- Kyorin Awards Spanish Pharma Rights to Uritos in Latin America
August 2, 2018
- Rxulti Gets European Approval for Schizophrenia: Otsuka/Lundbeck
August 1, 2018
- Takeda Completes TiGenix Acquisition
August 1, 2018
- Lenvima-Keytruda Combo Bags FDA’s Breakthrough Status for Endometrial Carcinoma
August 1, 2018
- Kyowa Hakko Kirin to Be Renamed Kyowa Kirin in July 2019
August 1, 2018
- Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
August 1, 2018
- Kyowa Kirin Sales Sag 2.8% but Net Profit Jumps on Capital Gains
August 1, 2018
- Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
August 1, 2018
- Takeda Integration Team Prepping for Shire Takeover: Weber
August 1, 2018
- AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
August 1, 2018
- Otsuka’s Guadecitabine Misses Primary Targets in Treatment-Naïve AML Patients in PIII
August 1, 2018
- Lonasen Patch Formulation Filed in Japan: Sumitomo Dainippon, Nitto Denko
August 1, 2018
- Eisai Grants Rights for Lorcaserin to Taiwan Biotech in China
August 1, 2018
- ASKA, Laboratoire HRA Strike Deal for IP Rights to Uterine Fibroid Treatment
August 1, 2018
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- Daiichi Sankyo Inks ADC License Pact with Glycotope
July 31, 2018
- Ono Seeks Add’l Indication for Onoact in Ventricular Arrhythmia
July 31, 2018
- Fujifilm to Shutter Gx, LLP Operations in March
July 30, 2018
- Mitsubishi Tanabe’s Erythropoietic Protoporphyria Earns FDA Fast-Track Status
July 30, 2018
- Chugai Forms Partnership with AI Upstart
July 30, 2018
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…